tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss WHO adds weight-loss, diabetes drugs

Nor does it explain another surprising finding from the study: men taking these weight-loss treatments appeared to face three times the risk of vision loss compared to women

If left untreated, hyperthyroidism can lead to major issues such as heart disease, bone loss, and, in severe circumstances, a life-threatening thyroid storm

Reduced potency from expired medication may mean your glucose levels are higher than expected

The peptide's predictable dose-response and extended stability in culture media have made it a preferred growth factor supplement in CHO cell culture, stem cell expansion, and primary cell isolation protocols across hundreds of published studies